Anti-GITR is proving to be another useful intervention checkpoint in cancer therapy.
Abstract 3813: Development of JNJ-64164711, a low fucose anti-GITR antibody for enhanced depletion of tumor regulatory T cells (Tregs)
Cam V. Holland, John Kehoe, Judith Hailey, Rupesh Nanjunda, Eilyn Lacy, Robin Ernst, Di Zhang, Sam Wu, Alexey Teplyakov, Weimin Li, Michelle Kinder, Edward W. Thompson, Patrick Wilkinson, Jackson Wong, Gerald Chu, Linda Okonkwo, John D. Alvarez, Anhco Nguyen, Iqbal S. Grewal, Moitreyee Chatterjee-Kishore, Mark Salvati and Marco Gottardis
DOI: 10.1158/1538-7445.AM2018-3813 Published July 2018
Related Ancell Products
anti-human GITR(CD357) mAb clone ANC5A3
anti-human GITR(CD357) mAb clone ANC7D6